About the event
T3 pharma is a spin-of from the Biozentrum of the University of Basel that has attracted extensive non-dilutive grant funding and has last year in record time also closed a seed round with private investors.
The company is exploiting on a naturally occurring bacterial protein secretion system that has been genetically engineered such that to solely deliver proteins of choice into the target cells. Together with the well-known bacterial preference of the bacteria to replicate at the site of solid tumors T3 pharma has created a highly efficient and targeted vehicle for delivery of therapeutic proteins into tumor cells forming the basis for the next generation cancer therapy.
This BaselArea.swiss & LSNB event at Halle 7 (Gundeldingerfeld, Dornacherstrasse 192) in Basel, on April 6th, 2017 (19:00; door opening 18:45), will have Simon Ittig, founder and CEO of T3 pharma, talking about this story and sharing insights and learnings along the way.
CV Simon Ittig
Simon completed a PhD on microbial pathogenesis at the University of Basel in the framework of the Werner Siemens Excellence fellowships. He started working on the T3 Pharma technology during his Post-doctoral studies at the Biozentrum. For this achievements he received the Novartis and University of Basel Excellence Scholarship in 2014.
Please register on the event page.